Fig. 6

Identification of predictive biomarkers for overall survival in pre-therapeutic tumor biopsies from trastuzumab-treated patients. a Distribution of gene expression values and Hazard ratios (HR) obtained for SHB (HR 1.5; 95% CI, 1 to 2.31), HAS2 (HR 1.7; 95% CI, 1.01 to 2.73) and BMF (HR 0.8; 95% CI, 0.44 to 1.3). SHB and HAS2 are risk factors for patient overall survival. The error bars show the 95% and boxes the 90% confidence interval. Green coloring shows significance. b Kaplan–Meier curves show the overall survival of patients with respect to HAS2 gene expression levels. Lower HAS2 gene expression measured in tumor biopsies is beneficial, whereas higher HAS2 gene expression is detrimental for patient overall survival under trastuzumab treatment. c Kaplan–Meier curves show the overall survival of patients in relation to SHB gene expression. Lower SHB gene expression measured in tumor biopsies is beneficial, whereas higher SHB gene expression is detrimental for patient overall survival under trastuzumab treatment. The method employed to obtain the p values was the log-rank test